PDS Appoints Ilian Iliev to the Board

RNS Number : 4687J

NetScientific PLC

14 April 2020

 

NetScientific plc

("NetScientific" or the "Company")

PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors

London, UK - 14 April 2020 - NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) announced on 9^th April 2020 the appointment of Dr. Ilian Iliev to its Board of Directors.

Below is the full announcement made today by PDS Biotechnology

#  #  #

PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors

PRINCETON, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® today announced that it has appointed Ilian Iliev, Ph.D. to its Board of Directors.

"We are very pleased to welcome Dr. Iliev to the Board of Directors. He brings a wealth of experience to PDS Biotech as a recognized entrepreneur and venture capitalist across multiple industries, including healthcare," commented Steve Glover, Chairman of the Board of PDS Biotech. "Together, we will help guide PDS Biotech through its near and long-term milestones as we advance our programs in infectious disease and immuno-oncology with leading research institutions and pharmaceutical companies."

Currently, Dr. Iliev is a Managing Director of EMV Capital, a London-based investor in B2B companies in the healthcare, transportation, energy and technology sectors. Previously he founded CambridgeIP, a boutique consultancy focused on IP commercialization based out of Cambridge, UK and working with clients in healthcare, energy and other sectors. Dr. Iliev is a Board Member of NetScientific PLC, a transatlantic healthcare IP commercialization group that funds and develops companies that are working to significantly improve the health and well-being of people with chronic diseases. He also serves on the Board of Directors of Sofant Technologies, Pointgrab, Q-Bot, Glycotest, Vortex Biosciences and Wanda Health.

Dr. Iliev holds a Ph.D. from Cambridge University's Judge Business School, focused on Venture Capital business models in emerging economies. He also received a Master of Commerce in Economics, and Bachelor of Arts in Politics, Economics and International Relations from the University of Witwatersrand. He has published widely on entrepreneurship, venture capital, and market trends in healthcare and energy and is an Associate Fellow at the Royal Institute of International Affairs

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of infectious disease vaccines and cancer immunotherapy based on the Company's proprietary Versamune® T-cell activating technology platform. The Versamune® platform effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of both neutralizing antibodies and potent disease-specific killer T-cells. Using Versamune®, PDS Biotech is engineering therapies designed to better recognize disease cells to effectively attack and destroy them. PDS Biotech's pipeline combines the Versamune® technology with disease-specific antigens across several therapeutic areas. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech

For more information, please contact:

NetScientific  Ian Postlethwaite, CEO/CFO	Tel: [phone]
WHIreland (NOMAD, Financial Adviser and Broker) Chris Fielding / Darshan Patel	Tel: [phone]
MO PR ADVISORY (Press Contact) Mo Noonan	Tel: [phone]

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. 

For more information, please visit the website at   www.NetScientific.net

 

END

 

 

NRAFLFFASEIVLII